References
- Leysen J E, Gommeren W, Van Gompel P, Wijnants J, Janssen P FM, Laduron P MJ. Receptor binding properties in vivo, in vitro of ritanserin. A very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 1985; 27: 600–11
- Meert T F, Niemegeers C JE, Awouters F, Janssen P AJ. Partiel and complete blockade of 5-hydroxy-tryptophan (5-HPT)-induced head twitches in the rat: A study of ritanserin (R 55 667), risperidon (R 64 766) and related compounds. Drug Dev Res 1988; 13: 237–44
- Idzikowski C, Mills F J, Glennard R. 5-Hydroxy-tryptamine-2 antagonist increases human slow wave sleep. Brain Res 1986; 378: 164–8
- Waelkens J, De Graeve W, Duyck H, et al. Double-blind comparison of ritanserin and placebo in anxiety and tension states accompanied with somatic symptoms. 1984, Clinical Research Report on R 55 667/1. Janssen Research Foundation
- Reyntjens A, Gelders Y G, Hoppenbrouwers M-L JA, Vanden Bussche G. Thymostenic effect of ritanserin (R 55 667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res 1986; 8: 205–11
- Tyrer P. Neurosis divisible?. Lancet 1985; Vol 1 or 2: 685–8
- Johnson D AW. A double blind comparison of flu-pentixol, nortriptyline and diazepam in neurotic depression. Acta Psychiatr Scand 1979; 59: 1–8
- Young J PR, Hughed W C, Lader M H. A controlled comparison of flupentizol and amitriptyline in depressed out-patients. Br Med J 1976; 1: 116–8
- Bech P, Kastrup M, Rafaelsen O J. Mini-compendium of rating scales for states of anxiety, depression, mania, and schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand 1986; 326(Suppl 73)
- Guy W. ECDEU assesment manual for psycho-pharmacology. National Institute of Mental Health, Rockville, Md.USA 1976; 76–338, DHEW publication no. (ADM)
- Lingjaerde O, Ahlfors U G, Bech P, Dencker S J, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic patients. Acta Psychiatr Scand 1987; 334(Suppl 76)
- Bech P, Gastpar M, Mendlewicz J. The role of training courses in multicenter trials: WHO experiences. Biological Psychiatry, C Chagass. Elsevier, Amsterdam 1986
- Arriaga F, Ruiz I, Lara E, Gelders Y G. Ritanserin, an original thymostenic for the treatment of dysthymia. A placebo-controlled study. XVth CINP Congress Abstract Book. 1986; 168
- Bersani G, Marini S, Grispini A, Pasini A, Ciani N. S2-antagonism (ritanserin) in dysthymic disorder. Psychopharmacology 1989; 96(Suppl 244)
- Sanders-Bush E, Tsutsumi M. Pharmacology, function and adaptive regulation of 5HT-1c receptors. Serotonin. From cell biology to pharmacology on therapeutics, R Paoletti, et al. Kluwer Academic Publishers, DordrechtThe Netherlands 1990; 309–15
- Carlson A. Preferential dopamine autoreceptor blockade: a possible pharmacotherapeutic principle in antidepressant therapy. Clin Neuropharmacol 1990; 13(Suppl 2)621–2
- Van Rooy P, Gelders Y, Vanden Bussche G, De Cree J. Double-blind placebo-controlled evaluation of various multiple doses of ritanserin on ECG and systolic time intervals in healthy volunteers. 1987, Clinical Research Report. N 59972. Janssen Research Foundation